For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Vedolizumab - Inflammatory bowel disease
PAD Profile : Vedolizumab - Inflammatory bowel disease Important
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.
The Surrey & North West Sussex Area Prescribing Committee recommends the use of vedolizumab subcutaneous injection or vedolizumab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.
Please note: Dose escalation with vedolizumab is not commissioned for either presentation, by the APC collaborative organisations.
NICE TA342 - Vedolizumab for the treatment of Ulcerative Colitis was published by NICE in June 2015. PCN members recommend the use of Vedolizumab as a treatment option in line with NICE guidance and a treatment pathway has been developed with local gastroenterologists.